Barinthus Biotherapeutics plc (NASDAQ:BRNS) — Market Cap & Net Worth
Market Cap & Net Worth: Barinthus Biotherapeutics plc (BRNS)
Barinthus Biotherapeutics plc (NASDAQ:BRNS) has a market capitalization of $22.78 Million ($22.78 Million) as of August 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #24637 globally and #5197 in its home market, demonstrating a -7.02% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Barinthus Biotherapeutics plc's stock price $0.56 by its total outstanding shares 40830353 (40.83 Million). See capital reinvestment ratio of Barinthus Biotherapeutics plc to understand how much of operating cash flow is reinvested back into capital assets.
Barinthus Biotherapeutics plc Market Cap History: 2021 to 2026
Barinthus Biotherapeutics plc's market capitalization history from 2021 to 2026. Data shows change from $453.63 Million to $22.78 Million (-46.07% CAGR).
Index Memberships
Barinthus Biotherapeutics plc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.00% | #699 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.00% | #2306 of 3165 |
Weight: Barinthus Biotherapeutics plc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Barinthus Biotherapeutics plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Barinthus Biotherapeutics plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.30x
Barinthus Biotherapeutics plc's market cap is 3.30 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $453.63 Million | $268.00K | -$50.87 Million | 1692.63x | N/A |
| 2022 | $95.95 Million | $44.70 Million | $5.34 Million | 2.15x | 17.96x |
| 2023 | $150.66 Million | $802.00K | -$73.35 Million | 187.86x | N/A |
| 2024 | $49.32 Million | $14.97 Million | -$61.07 Million | 3.30x | N/A |
Competitor Companies of BRNS by Market Capitalization
Companies near Barinthus Biotherapeutics plc in the global market cap rankings as of August 3, 2026.
Key companies related to Barinthus Biotherapeutics plc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Barinthus Biotherapeutics plc Historical Marketcap From 2021 to 2026
Between 2021 and today, Barinthus Biotherapeutics plc's market cap moved from $453.63 Million to $ 22.78 Million, with a yearly change of -46.07%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $22.78 Million | -20.30% |
| 2025 | $28.59 Million | -42.04% |
| 2024 | $49.32 Million | -67.26% |
| 2023 | $150.66 Million | +57.02% |
| 2022 | $95.95 Million | -78.85% |
| 2021 | $453.63 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 3rd, 2026 the market cap of Barinthus Biotherapeutics plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $22.78 Million USD |
| MoneyControl | $22.78 Million USD |
| MarketWatch | $22.78 Million USD |
| marketcap.company | $22.78 Million USD |
| Reuters | $22.78 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Barinthus Biotherapeutics plc
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases. Its lead candidate is VTP-1000, which is in Phase 1 clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease. The company is also developing VTP-300, an immunotherapeutic targetin… Read more